Caspofungin (MK-0991) Acetate

Catalog No.S3073 Synonyms: L-743872

For research use only.

Caspofungin Acetate (MK-0991, L-743872) is an lipopeptide antifungal β-1,3-glucan synthase inhibitor.

Caspofungin (MK-0991) Acetate Chemical Structure

CAS No. 179463-17-3

Selleck's Caspofungin (MK-0991) Acetate has been cited by 13 publications

Purity & Quality Control

Choose Selective Fungal Inhibitors

Biological Activity

Description Caspofungin Acetate (MK-0991, L-743872) is an lipopeptide antifungal β-1,3-glucan synthase inhibitor.
Targets
β-1,3-glucan synthase [3]
In vitro

Caspofungin acetate is the first in a new class of antifungals that inhibits the synthesis of beta (1, 3)-d-glucan, an essential component of the cell wall of filamentous fungi. Prior studies have shown in vitro activity of caspofungin acetate using the reference methods, broth microdilution or macrodilution, for antifungal susceptibility testing of Candida species established by the National Committee for Clinical Laboratory Standards 1997 guidelines against a variety of Candida species including Candida krusei. Although caspofungin acetate is only Food and Drug Administration-approved for the treatment of aspergillosis, there is information showing that many Candida species are susceptible. The minimal inhibitory concentration for 90% inhibition of Candida species by caspofungin acetate are as follows:C. albicans 0.5 μg/mL (range, 0.25-0.5), C. glabrata 1.0 μg/mL (range, 0.25-2.0), C. tropicalis 1.0 μg/mL (range, 0.25-1.0), C. parapsilosis 0.5 μg/mL (range, 0.25-1.0), and C. krusei 2.0 μg/mL (range, 0.5-2.0)

Protocol (from reference)

Solubility (25°C)

In vitro

Water 100 mg/mL
(82.41 mM)
Ethanol '''-1 mg/mL

Chemical Information

Molecular Weight 1213.42
Formula

C52H88N10O15.2C2H4O2

CAS No. 179463-17-3
Storage 3 years -20°C(in the dark) powder
2 years -80°C(in the dark) in solvent
Smiles CCC(C)CC(C)CCCCCCCCC(=O)NC1CC(C(NC(=O)C2C(CCN2C(=O)C(NC(=O)C(NC(=O)C3CC(CN3C(=O)C(NC1=O)C(C)O)O)C(C(C4=CC=C(C=C4)O)O)O)C(CCN)O)O)NCCN)O.CC(=O)O.CC(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04674657 Recruiting Drug: blood drug concentration Critical Illness|Extracorporeal Membrane Oxygenation Complication|Infection Royal Brompton & Harefield NHS Foundation Trust September 3 2018 --
NCT03399032 Unknown status Drug: Caspofungin Septic Shock|Fungal Infection|Critical Illness Medical University of Lublin February 5 2018 --
NCT02805049 Completed Drug: Echinocandins Septic Shock|Peritonitis Centre Hospitalier Universitaire de Nīmes January 28 2017 Phase 4
NCT03798600 Completed Drug: Caspofungin Critical Illness|Infection Careggi Hospital January 1 2016 --
NCT02596984 Completed Drug: Caspofungin Shock Centre Hospitalier Universitaire de Saint Etienne|Merck Sharp & Dohme Corp. March 16 2015 Not Applicable
NCT01994096 Completed Drug: Caspofungin Critically Ill|Suspected Invasive Candidiasis University Medical Center Groningen November 2013 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Caspofungin (MK-0991) Acetate | Caspofungin (MK-0991) Acetate supplier | purchase Caspofungin (MK-0991) Acetate | Caspofungin (MK-0991) Acetate cost | Caspofungin (MK-0991) Acetate manufacturer | order Caspofungin (MK-0991) Acetate | Caspofungin (MK-0991) Acetate distributor